Loading...

CardieX

ASX:CDX
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CDX
ASX
A$27M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

CardieX Limited designs, manufactures, and markets medical devices for use in cardiovascular health management in the Americas, Europe, and the Asia Pacific. The last earnings update was 54 days ago. More info.


Add to Portfolio Compare Print
  • CardieX has significant price volatility in the past 3 months.
CDX Share Price and Events
7 Day Returns
0%
ASX:CDX
3.2%
AU Medical Equipment
-0%
AU Market
1 Year Returns
73.9%
ASX:CDX
-2.2%
AU Medical Equipment
4.6%
AU Market
CDX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
CardieX (CDX) 0% -2.4% -11.1% 73.9% -75% -68%
AU Medical Equipment 3.2% -0.5% 0.8% -2.2% 38.7% 105%
AU Market -0% 1% 6.9% 4.6% 18.2% 4.8%
1 Year Return vs Industry and Market
  • CDX outperformed the Medical Equipment industry which returned -2.2% over the past year.
  • CDX outperformed the Market in Australia which returned 4.6% over the past year.
Price Volatility
CDX
Industry
5yr Volatility vs Market

Value

 Is CardieX undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for CardieX. This is due to cash flow or dividend data being unavailable. The share price is A$0.04.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for CardieX's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are CardieX's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:CDX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.01
ASX:CDX Share Price ** ASX (2019-04-23) in AUD A$0.04
Australia Medical Equipment Industry PE Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 33.38x
Australia Market PE Ratio Median Figure of 544 Publicly-Listed Companies 16.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of CardieX.

ASX:CDX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:CDX Share Price ÷ EPS (both in AUD)

= 0.04 ÷ -0.01

-5.32x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CardieX is loss making, we can't compare its value to the AU Medical Equipment industry average.
  • CardieX is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does CardieX's expected growth come at a high price?
Raw Data
ASX:CDX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.32x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Oceania Medical Equipment Industry PEG Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 2.62x
Australia Market PEG Ratio Median Figure of 360 Publicly-Listed Companies 1.35x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for CardieX, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on CardieX's assets?
Raw Data
ASX:CDX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.01
ASX:CDX Share Price * ASX (2019-04-23) in AUD A$0.04
Australia Medical Equipment Industry PB Ratio Median Figure of 30 Publicly-Listed Medical Equipment Companies 2.72x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.67x
ASX:CDX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:CDX Share Price ÷ Book Value per Share (both in AUD)

= 0.04 ÷ 0.01

4.12x

* Primary Listing of CardieX.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CardieX is overvalued based on assets compared to the AU Medical Equipment industry average.
X
Value checks
We assess CardieX's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. CardieX has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is CardieX expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CardieX has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.2%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is CardieX expected to grow at an attractive rate?
  • Unable to compare CardieX's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare CardieX's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare CardieX's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:CDX Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13.2%
Australia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:CDX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:CDX Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
ASX:CDX Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 4 -3 -3
2018-09-30 4 -2 -3
2018-06-30 4 -2 -3
2018-03-31 5 -2 -3
2017-12-31 5 -2 -4
2017-09-30 5 -3 -4
2017-06-30 5 -3 -4
2017-03-31 5 -4 -4
2016-12-31 5 -4 -4
2016-09-30 5 -5 -5
2016-06-30 5 -5 -5
2016-03-31 5 -4 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if CardieX is high growth as no earnings estimate data is available.
  • Unable to determine if CardieX is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:CDX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from CardieX Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:CDX Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
ASX:CDX Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.01
2018-09-30 -0.01
2018-06-30 -0.01
2018-03-31 -0.01
2017-12-31 -0.01
2017-09-30 -0.02
2017-06-30 -0.02
2017-03-31 -0.02
2016-12-31 -0.02
2016-09-30 -0.02
2016-06-30 -0.02
2016-03-31 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if CardieX will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine CardieX's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. CardieX's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. CardieX's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess CardieX's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
CardieX has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has CardieX performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare CardieX's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • CardieX does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare CardieX's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare CardieX's 1-year growth to the AU Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
CardieX's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from CardieX Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:CDX Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 4.40 -3.25 4.78 1.69
2018-09-30 4.41 -3.10 4.67 1.62
2018-06-30 4.42 -2.96 4.56 1.54
2018-03-31 5.09 -3.27 4.82 1.40
2017-12-31 5.34 -3.58 5.07 1.25
2017-09-30 5.07 -3.97 5.67 1.36
2017-06-30 4.80 -4.36 6.28 1.48
2017-03-31 4.99 -4.37 6.96 1.54
2016-12-31 5.17 -4.38 7.65 1.61
2016-09-30 5.09 -4.59 7.69 1.60
2016-06-30 5.02 -4.81 7.74 1.59
2016-03-31 4.66 -4.29 7.14 1.67
2015-12-31 4.30 -3.78 6.54 1.75
2015-09-30 4.88 -2.61 6.19 1.68
2015-06-30 5.47 -1.44 5.83 1.62
2015-03-31 5.35 -1.55 5.73 1.50
2014-12-31 5.24 -1.66 5.62 1.38
2014-09-30 5.15 -2.16 5.72 1.38
2014-06-30 5.05 -2.66 5.83 1.38
2014-03-31 5.68 -1.58 5.78 1.39
2013-12-31 6.30 -0.49 5.73 1.39
2013-09-30 7.68 1.12 5.56 1.42
2013-06-30 9.06 2.73 5.39 1.44
2013-03-31 8.56 1.93 5.46 1.57
2012-12-31 8.06 1.13 5.52 1.70
2012-09-30 7.25 -0.43 5.76 1.90
2012-06-30 6.44 -1.99 6.00 2.11

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if CardieX has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if CardieX has efficiently used its assets last year compared to the AU Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if CardieX improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess CardieX's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
CardieX has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is CardieX's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up CardieX's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • CardieX is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • CardieX's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of CardieX's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • CardieX has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from CardieX Company Filings, last reported 3 months ago.

ASX:CDX Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 6.13 0.00 4.74
2018-09-30 6.13 0.00 4.74
2018-06-30 4.60 0.19 2.74
2018-03-31 4.60 0.19 2.74
2017-12-31 1.44 0.00 0.72
2017-09-30 1.44 0.00 0.72
2017-06-30 1.33 0.00 0.68
2017-03-31 1.33 0.00 0.68
2016-12-31 2.82 0.00 1.75
2016-09-30 2.82 0.00 1.75
2016-06-30 3.14 0.00 1.77
2016-03-31 3.14 0.00 1.77
2015-12-31 4.90 0.00 3.78
2015-09-30 4.90 0.00 3.78
2015-06-30 4.33 0.00 3.45
2015-03-31 4.33 0.00 3.45
2014-12-31 3.91 0.00 2.52
2014-09-30 3.91 0.00 2.52
2014-06-30 3.28 0.00 2.17
2014-03-31 3.28 0.00 2.17
2013-12-31 4.71 0.00 4.10
2013-09-30 4.71 0.00 4.10
2013-06-30 4.88 0.00 2.87
2013-03-31 4.88 0.00 2.87
2012-12-31 4.43 0.00 2.14
2012-09-30 4.43 0.00 2.14
2012-06-30 1.88 0.00 1.12
  • CardieX has no debt.
  • CardieX had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • CardieX has sufficient cash runway for 1.7 years based on current free cash flow.
  • CardieX has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of -28.1% each year.
X
Financial health checks
We assess CardieX's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. CardieX has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is CardieX's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from CardieX dividends.
If you bought A$2,000 of CardieX shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate CardieX's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate CardieX's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:CDX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Oceania Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.7%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.3%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:CDX Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as CardieX has not reported any payouts.
  • Unable to verify if CardieX's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of CardieX's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as CardieX has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess CardieX's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can CardieX afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. CardieX has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of CardieX's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Craig Cooper
COMPENSATION A$391,595
TENURE AS CEO 1.3 years
CEO Bio

Mr. Craig R. Cooper is the Co-Owner at C2 Ventures Pty Ltd and Chief Executive Officer, Managing Director and Executive Director at AtCor Medical Holdings Limited since December 01, 2017. Mr. Cooper is a Managing Partner at Cooper Capital Partners. He is Founder of CooperativeHealth LLC and serves as its Chairman and Chief Executive Officer. He is Founder and Chairman of Prostate Cancer Institute, LLC. He served as Chairman and Founder of JoMo Nutrition USA, LLC. Mr. Cooper served as a Managing Director at Saban Ventures. He served as Managing Director and Head of Venture Capital and Digital Media at Saban Capital Group, Inc. He served as Managing Director at saban since March 10, 2008. Mr. Cooper was a Venture Partner at VantagePoint Venture Partners (now known as VantagePoint Capital Partners). He is recognised as a global expert and thought leader in mobile and wireless technology as well as digital health and med-tech-related businesses. Mr. Cooper was a Founding Partner at SOFTBANK Capital Technology Fund III L.P. and SoftBank Capital, where he led the West Coast Digital Media and Wireless Investment Group. He focused on wireless services, mobile content, applications and media. Prior to joining SoftBank Capital in 2004, he was a Co-Founder at Boost Mobile LLC and Boost Mobile USA. Mr. Cooper was a Principal at Mercury Capital and Mercury Capital Partners, where he advised on a number of wireless and technology related ventures as well as initial public offerings. He has been a Founder or Co-Founder of a number of technology and media companies throughout his career. Mr. Cooper served as a Senior Associate at Ashurst Australia. He has also served as a Private Equity Adviser at Bank of Singapore Limited in Sydney and as a Senior Associate at Blake Dawson Waldron, where he acted for clients such as United Airlines, The Disney Corporation and DHL International, where Mr. Cooper was an External General Counsel. In 1994, he co-founded NRG Asia-Pacific Ltd. Earlier, Mr. Cooper was also a Founding Principal at Private Energy Partners. He also held the position of the Chief Executive Officer at E-world Technologies Limited and was also a Partner in the largest independent mobile retail distribution company in Australia. Mr. Cooper was also a personal advisor to Tony Robbins and The Anthony Robbins Group of Companies on various online and digital projects. He serves as Director of Mr. Number Inc., Amptech, Inc., Learning Annex Holdings LLC (now known as Learning Annex, LP) and Skydeck, Inc. He served as a Director at Insider Pages, Inc. Mr. Cooper served as a Member of Advisory Board at Ubiquity, Inc. since March 28, 2012. He served as Advisor and Director at PureVideo Networks Inc. He served as Director of EBT Mobile China plc from October 2005 to November 03, 2006. He served as Director of Next New Networks Inc., ThumbPlay, Inc., (now known as ThumbPlay Ringtones, LLC), YouMail, Inc., Perpetual Entertainment, Inc. and Nellymoser, Inc. Mr. Cooper is a Contributing Expert on Men's Health, Lifestyle, Exercise and Nutrition to The Huffington Post. Mr. Cooper was named one of Hollywood's Top Dealmakers in 2008. Mr. Cooper received a Bachelor of Economics and a Bachelor of Laws, with honors, from the University of Sydney.

CEO Compensation
  • Insufficient data for Craig to compare compensation growth.
  • Craig's remuneration is about average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the CardieX management team in years:

1.1
Average Tenure
  • The average tenure for the CardieX management team is less than 2 years, this suggests a new team.
Management Team

Craig Cooper

TITLE
CEO, MD & Director
COMPENSATION
A$392K
TENURE
1.3 yrs

Jarrod White

TITLE
CFO & Company Secretary
TENURE
1.1 yrs

ZiHan Lin

TITLE
Vice President of Corporate Development
TENURE
0.8 yrs

Doug Kurschinski

TITLE
Executive VP & Head of Global Sales for AtCor Medical Division
COMPENSATION
A$361K
Board of Directors Tenure

Average tenure of the CardieX board of directors in years:

0.8
Average Tenure
  • The average tenure for the CardieX board of directors is less than 3 years, this suggests a new board.
Board of Directors

Niall Charles Cairns

TITLE
Interim Chairman of the Board
COMPENSATION
A$28K
AGE
54
TENURE
0.2 yrs

Craig Cooper

TITLE
CEO, MD & Director
COMPENSATION
A$392K
TENURE
1.3 yrs

Randall Nelson

TITLE
Independent Non-Executive Director
COMPENSATION
A$28K
AGE
61
TENURE
3.4 yrs

Rhonda Welch

TITLE
Member of Advisory Board
TENURE
0.8 yrs

Harry Kim

TITLE
Special Advisor
TENURE
0.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
04. Jul 18 Buy Paul Cozzi Individual 02. May 18 02. May 18 2,735,174 A$0.02 A$54,700
04. Jul 18 Buy Paul Cozzi Individual 15. Jan 18 05. Jun 18 7,164,826 A$0.03 A$192,836
05. Jun 18 Buy Donal O’Dwyer Individual 05. Jun 18 05. Jun 18 5,000,000 A$0.02 A$99,999
X
Management checks
We assess CardieX's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. CardieX has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

CardieX Limited designs, manufactures, and markets medical devices for use in cardiovascular health management in the Americas, Europe, and the Asia Pacific. The company offers SphygmoCor system for central arterial pressure waveform analysis and blood pressure management. Its products comprise SphygmoCor XCEL, a device for noninvasive measurement of central arterial pressure waveform analysis and arterial stiffness assessment; SphygmoCor XCEL pulse wave analysis (PWA), a device to measure central aortic systolic blood pressure, central pulse pressure, and augmentation index; SphygmoCor XCEL PWA and PWV, a device for carotid-femoral PWV measurement; and SphygmoCor Cardiovascular Management System (CVMS), a device used to non-invasively obtain cardiovascular data that cannot be obtained with traditional brachial cuff blood pressure measurements. The company also provides clinical trial services, such study protocol design assistance, personalized end-user training, and data management and site support. It offers its devices and services to hospitals, research institutions, pharmaceutical companies, and clinicians. CardieX Limited has strategic collaboration with Blumio Inc. to develop an intelligent sensor technology that can be integrated into a range of consumer and medical wearable devices. The company was formerly known as AtCor Medical Holdings Limited and changed its name to CardieX Limited in June 2018. CardieX Limited is based in West Ryde, Australia.

Details
Name: CardieX Limited
CDX
Exchange: ASX
Founded:
A$27,124,586
695,502,228
Website: http://www.atcormedical.com
Address: CardieX Limited
1059 - 1063 Victoria Road,
Suite 11,
West Ryde,
New South Wales, 2114,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX CDX Ordinary Shares Australian Securities Exchange AU AUD 09. Nov 2005
OTCPK AMDH.F Ordinary Shares Pink Sheets LLC US USD 09. Nov 2005
Number of employees
Current staff
Staff numbers
0
CardieX employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 10:33
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2016/08/29
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.